muscarinic M1 and M4 receptor partial agonist (Sumitomo Dainippon)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug Namemuscarinic M1 and M4 receptor partial agonist (Sumitomo Dainippon)

Drug Alias Namemuscarinic M1 and M4 receptor agonist (Dainippon Sumitomo)muscarinic M1 and M4 receptor partial agonist (Dainippon Sumitomo)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionMuscarinic acetylcholine receptor M1 agonistsMuscarinic acetylcholine receptor M4 agonistsMuscarinic acetylcholine receptor M1 partial agonists

TargetsMuscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M4

Therapy Area/IndicationsCentral Nervous System Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSumitomo Pharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSumitomo Pharmaceuticals Co Ltd

Active IndicationsN/A

Inactive IndicationsCentral Nervous System Diseases

Other Information

ATC CodeN/A